Modality
Peptide
MOA
PRMT5i
Target
SOS1
Pathway
Angiogenesis
MesoThymomaAlzheimer's
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
May 2020
→ Dec 2028
Phase 1Current
NCT05658977
2,804 pts·Meso
2020-05→2028-12·Active
NCT05261799
75 pts·Alzheimer's
2021-05→2028-12·Terminated
2,879 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-09-276mo agoBTD· Meso
2028-12-222.7y awayInterim· Meso
2028-12-232.7y awayInterim· Alzheimer's
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Active
P1
Termina…
Catalysts
BTD
2025-09-27 · 6mo ago
Meso
Interim
2028-12-22 · 2.7y away
Meso
Interim
2028-12-23 · 2.7y away
Alzheimer's
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05658977 | Phase 1 | Meso | Active | 2804 | PANSS |
| NCT05261799 | Phase 1 | Alzheimer's | Terminated | 75 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP |